The safety of Canada’s plasma supply is under renewed scrutiny following reports of serious adverse reactions, including the deaths of two individuals, after donating plasma at private clinics. These incidents, coupled with recent failed inspections of Grifols facilities and concerns over the increasing prevalence of for-profit plasma collection, are prompting calls for tighter regulation and a re-evaluation of Canada’s approach to blood and plasma donation. The core issue revolves around the balance between ensuring a sufficient plasma supply – vital for creating life-saving medications – and safeguarding the health of donors and maintaining public trust in the system.
Plasma, the liquid portion of blood, is a critical component in the production of therapies for a range of conditions, including hemophilia, immune deficiencies, and burn treatment. Canada has faced increasing pressure to bolster its domestic plasma supply, leading to a greater reliance on private companies like Grifols, a Spanish healthcare firm, to collect plasma from donors. This shift towards a compensated donation model, where donors receive payment for their time, has raised concerns about potential risks, including the possibility of individuals concealing health information to qualify for donation, and the potential for exploitation of vulnerable populations. The current situation demands a careful examination of the safeguards in place and whether they are adequate to protect donor safety and the integrity of the blood supply.
Health Canada is currently investigating the deaths of two plasma donors in Winnipeg, Manitoba, who donated at Grifols-operated clinics. According to reports from CBC News, the deaths occurred in October 2025 and January 2026, with both donors experiencing “distress” during the donation process. A third individual has also filed a lawsuit alleging kidney damage following a plasma donation at a Grifols center. These incidents coincide with recent failed inspections at Grifols facilities in Calgary and Regina, where inspectors found deficiencies in donor screening procedures, as reported by Health Canada’s drug inspection database. The Calgary inspection report and the Regina inspection report both highlight concerns regarding inadequate assessment of donor eligibility.
Growing Concerns Over For-Profit Plasma Collection
The rise of for-profit plasma collection centers in Canada has sparked debate about the potential risks to the safety and sustainability of the blood supply. Critics argue that the financial incentive for companies to collect plasma can lead to compromised screening processes and a greater willingness to accept donations from individuals who may not be suitable donors. The Canadian Health Services Federation (SCSF) strongly opposes compensated plasma donation, viewing it as a dangerous privatization of the Canadian blood supply system. The SCSF contends that this practice undermines the principles of voluntary donation, which have historically been the cornerstone of Canada’s blood safety record, and contradicts recommendations stemming from the Krever Inquiry, a public investigation into the tainted blood scandal of the 1980s.
The Krever Inquiry, established in 1997, investigated the circumstances surrounding the contamination of Canada’s blood supply with HIV and hepatitis C, resulting in thousands of infections and deaths. The inquiry’s final report, released in 1997, made numerous recommendations aimed at strengthening the safety and oversight of the blood system, emphasizing the importance of a non-profit, voluntary donation model. The SCSF points to a 2022 agreement between Canadian Blood Services (CBS) and Grifols as a concerning step towards privatization, allowing Grifols to take on a larger role in plasma collection within Ontario. This agreement, the SCSF argues, opened the door to for-profit plasma collection and prioritized financial gain over donor safety.
While deaths related to plasma donation are considered exceedingly rare, experts acknowledge that they can occur due to equipment malfunction or inadequate procedures. Insufficient donor evaluation and inadequate staff training are also potential contributing factors. These risks are amplified, critics say, when private companies prioritize profit over safety. The potential for donors to withhold crucial health information in exchange for compensation is a significant concern, as is the possibility of exploiting vulnerable individuals who may be more likely to donate frequently due to financial demand. The promise of payment can create a situation where individuals may not fully understand the risks associated with plasma donation or may be pressured to donate even if they are not feeling well.
Health Canada Investigations and Regulatory Response
Health Canada has confirmed it is investigating the recent deaths and is working with Grifols to gather more information. In a statement released on March 12, 2026, Canadian Blood Services expressed its sadness over the deaths and stated it is in contact with Grifols and Health Canada. Canadian Blood Services emphasized that all donation centers in Canada, regardless of whether donors are paid or not, are licensed by Health Canada and must adhere to stringent regulations. However, the agency also acknowledged that serious health events are exceedingly rare and that, at this time, there is no evidence to suggest a direct correlation between the deaths and the donation process.
Despite this assertion, the recent incidents have prompted calls for increased oversight of plasma collection centers and a review of existing regulations. The SCSF is urging the federal government to strengthen and adequately fund the Blood System Safety Contribution Program (BSSCP), which is scheduled to be defunded on March 31, 2026. The BSSCP was established in the wake of the tainted blood scandal to enhance the safety of Canada’s blood supply. The SCSF argues that defunding this program, coupled with the expansion of private plasma collection, will inevitably increase risks for both donors and recipients of blood products. The potential for supply imbalances and a decline in public trust are also cited as concerns.
Grifols Response and Ongoing Concerns
Grifols has issued a statement indicating it has “no reason to believe that there is a correlation between the donors’ passing and plasma donation,” as reported by The Guardian on March 12, 2026. The company maintains that it operates under strict safety protocols and is cooperating fully with Health Canada’s investigation. However, the recent inspection failures and the ongoing investigations raise questions about the effectiveness of these protocols and the level of oversight provided by regulatory authorities. The company operates 17 facilities across Canada and plays a significant role in the country’s plasma collection efforts.
According to CBC News, four people have died in Canada after donating plasma in the last decade, with three of those deaths occurring in Manitoba. This data, reported on March 13, 2026, underscores the need for continued vigilance and a thorough investigation into the potential risks associated with plasma donation. The SCSF and other advocacy groups are calling for greater transparency in the plasma collection process, including public access to inspection reports and data on adverse events. They also advocate for a return to a predominantly voluntary donation system, arguing that it is the most effective way to ensure the safety and sustainability of Canada’s blood supply.
The Future of Plasma Donation in Canada
The current situation presents a critical juncture for Canada’s blood and plasma system. The decision to defund the BSSCP on March 31, 2026, will have significant implications for the safety and security of the blood supply. Without adequate funding for oversight and quality control, the risks associated with private plasma collection are likely to increase. The ongoing investigations into the recent deaths and the failed inspections of Grifols facilities highlight the urgent need for a comprehensive review of Canada’s plasma donation policies and regulations.
Moving forward, a collaborative approach involving Health Canada, Canadian Blood Services, Grifols, and patient advocacy groups is essential. This collaboration should focus on strengthening donor screening procedures, improving staff training, enhancing oversight of plasma collection centers, and ensuring transparency in the reporting of adverse events. The goal must be to protect the health of donors and recipients while maintaining a reliable and sustainable supply of life-saving plasma products. The debate over compensated plasma donation is likely to continue, but the recent events underscore the importance of prioritizing safety and public trust above all else.
Health Canada is expected to release an update on its investigation into the deaths of the two plasma donors in the coming weeks. Further developments in the case, as well as any potential changes to plasma donation regulations, will be closely monitored. We encourage readers to share their thoughts and experiences with Canada’s plasma donation system in the comments below.